Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.77 | 6.52 | 6.31 | 4.92 | 3.14 | 2.21 | 2.19 | 1.03 | 0.75 | 0.66 | 0.42 | 0.67 | 0.63 | 0.50 | 0.30 | 2.19 | 1.13 | 1.11 | 12.71 | 5.04 | 6.16 |
| — | +195.4% | +187.6% | +379.3% | +317.4% | +232.2% | +427.2% | +52.5% | +19.1% | +32.3% | +37.3% | -69.2% | -44.2% | -55.0% | -97.6% | -56.6% | -81.6% | -95.4% | +20.3% | +69.1% | +299.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | -0.45 | -1.30 | — | — | 0.07 | 0.06 | 1.64 | — | 2.39 |
| — | — | — | — | — | — | — | — | — | — | — | — | -704.7% | -2357.2% | — | — | -96.9% | -98.7% | +430.5% | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.6% | -15.6% | -14.8% | -16.1% | -15.8% | -10.2% | -10.3% | -6.6% | -7.5% | -33.6% | -37.0% | -33.3% | -16.1% | -8.0% | -17.8% | -93.6% | -54.3% | -68.2% | -93.0% | -55.9% | -87.2% |
| — | -52.9% | -43.5% | -142.7% | -112.2% | +69.6% | +72.1% | +80.1% | +53.6% | -317.1% | -107.5% | +64.4% | +70.4% | +88.2% | +80.8% | -67.4% | +37.7% | +9.3% | +84.9% | -18.9% | -104.9% | |
| ROA | -52.4% | -14.5% | -13.8% | -15.0% | -15.1% | -10.0% | -10.0% | -6.4% | -7.2% | -28.5% | -29.1% | -27.4% | -15.2% | -7.5% | -15.1% | -62.6% | -44.5% | -47.3% | -55.9% | -43.1% | -64.4% |
| — | -46.1% | -38.6% | -135.3% | -111.1% | +65.1% | +65.7% | +76.7% | +52.8% | -277.8% | -92.9% | +56.3% | +65.9% | +84.0% | +73.1% | -45.3% | +30.8% | -2.6% | +86.5% | -20.8% | -108.1% | |
| ROIC | — | — | — | — | — | — | — | — | — | -8571.4% | — | — | 643.1% | 336.8% | -417.0% | -5471.3% | 1789.3% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | -2645.2% | — | — | -64.1% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | 0.03 | 0.03 | 0.06 | 0.02 | 0.03 | 0.04 | 0.54 | 0.05 | 0.05 | 0.31 | 0.07 | 0.04 |
| — | — | — | — | — | — | — | — | — | +20.1% | -7.6% | -88.6% | -71.1% | -46.4% | -88.3% | +690.0% | +22.6% | -78.9% | +245.7% | +3.9% | -3.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 0.08 | 0.28 | — | — | 0.07 | 0.11 | 0.18 | — | 0.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | +14.7% | +144.1% | — | — | -13.0% | -33.1% | +1453.0% | — | — | |
| Current Ratio | 14.56 | 15.07 | 14.52 | 14.56 | 15.58 | 41.89 | 40.48 | 20.60 | 38.95 | 6.10 | 7.12 | 3.26 | 19.73 | 17.04 | 15.52 | 1.74 | 6.54 | 5.60 | 1.75 | 3.64 | 5.87 |
| — | -64.0% | -64.1% | -29.3% | -60.0% | +586.9% | +468.5% | +532.4% | +97.4% | -64.2% | -54.1% | +87.6% | +201.6% | +204.1% | +787.4% | -52.3% | +11.4% | +160.0% | -44.5% | +13.4% | -9.0% | |
| Quick Ratio | 14.56 | 15.07 | 14.52 | 14.56 | 15.58 | 41.89 | 40.48 | 20.60 | 38.95 | 6.10 | 7.12 | 3.26 | 19.73 | 17.04 | 15.52 | 1.74 | 6.54 | 5.60 | 1.75 | 3.64 | 5.87 |
| — | -64.0% | -64.1% | -29.3% | -60.0% | +586.9% | +468.5% | +532.4% | +97.4% | -64.2% | -54.1% | +87.6% | +201.6% | +204.1% | +787.4% | -52.3% | +11.4% | +160.0% | -44.5% | +13.4% | -9.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | -626.45 | -388.07 | -476.08 | -1496.49 | -368.49 | -120.23 | -190.40 | — | -7839.15 | -1926.91 | -1051.00 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TENX stock.
Tenax Therapeutics, Inc.'s current P/E is -1.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tenax Therapeutics, Inc.'s business trajectory between earnings reports.